Noé Ochida
@noeochida.bsky.social
Postdoc in infectious disease modelling at Institut Pasteur
Reposted by Noé Ochida
Important differences in excess mortality were reported in Europe during the COVID19 pandemic. To explain them, we examined patterns in age- and sex-standardized cumulative excess mortality in 13 Western European countries. 🧪
bmcglobalpublichealth.biomedcentral.com/articles/10....
bmcglobalpublichealth.biomedcentral.com/articles/10....
Patterns and drivers of excess mortality during the COVID-19 pandemic in 13 Western European countries - BMC Global and Public Health
Background Important differences in excess mortality between European countries during the COVID-19 pandemic have been reported. Understanding the drivers of these differences is essential to pandemic...
bmcglobalpublichealth.biomedcentral.com
December 9, 2024 at 8:19 AM
Important differences in excess mortality were reported in Europe during the COVID19 pandemic. To explain them, we examined patterns in age- and sex-standardized cumulative excess mortality in 13 Western European countries. 🧪
bmcglobalpublichealth.biomedcentral.com/articles/10....
bmcglobalpublichealth.biomedcentral.com/articles/10....
Reposted by Noé Ochida
Just few days to go to apply to our 1-week course on Infectious Disease Mathematical Modelling at Institut Pasteur in Paris next April. Come to join us for exciting scientific discussions!
Join our 1-week course on Infectious Disease Mathematical Modelling at Institut Pasteur in beautiful Paris, April 7-11 2025! Deadline for applications: 7 December 2024.
More information at www.pasteur.fr/en/education...
More information at www.pasteur.fr/en/education...
December 3, 2024 at 10:39 AM
Just few days to go to apply to our 1-week course on Infectious Disease Mathematical Modelling at Institut Pasteur in Paris next April. Come to join us for exciting scientific discussions!
Reposted by Noé Ochida
During the 2023-24 RSV season, France administered ~215k doses of new monoclonal antibody nirsevimab to newborns. In LancetChildAdolescHealth, we evaluated the impact of this policy on the number of hospitalizations for RSV bronchiolitis following ER visits.
hal.science/pasteur-0450...
hal.science/pasteur-0450...
Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study
Background: Respiratory syncytial virus (RSV) is a major cause of hospitalisations and deaths among infants worldwide. France was one of the first countries to implement a national programme (beginnin...
hal.science
November 20, 2024 at 1:49 PM
During the 2023-24 RSV season, France administered ~215k doses of new monoclonal antibody nirsevimab to newborns. In LancetChildAdolescHealth, we evaluated the impact of this policy on the number of hospitalizations for RSV bronchiolitis following ER visits.
hal.science/pasteur-0450...
hal.science/pasteur-0450...